Fnx Performance products are intended strictly for qualified in vitro laboratory research. For Research Use Only. Not for human or animal consumption. Not for compounding or therapeutic application.
Semax, Synthetic heptapeptide
A synthetic heptapeptide analog of ACTH(4-10) with CNS activity but no corticotropic effect, used in Russia as a nootropic/neuroprotective agent.

A heptapeptide derived from ACTH but stripped of its hormonal effect, used in Russia to raise BDNF and protect the brain, especially after stroke.
Neuroprotection
Nootropic
BDNF upregulation
Bars indicate how far the evidence has progressed (in vitro to animal to human), not the size of any effect.
Gusev EI, Skvortsova VI, et al.
In 30 acute stroke patients given Semax plus intensive therapy vs 80 controls, Semax was associated with faster regression of cerebral and focal motor deficits (effect sizes not reported).
A registered prescription nootropic in Russia (since ~2011) used for stroke/cognitive impairment; Russian studies support neuroprotection, attention, and memory, especially post stroke. Trials are mostly small, single institution, Russian language, rarely blinded to Western standards, and largely absent from FDA databases.
Generally well tolerated in Russian use; long term and Western safety data are lacking.
Russia registered; not FDA approved. Category 2 (2023), removed April 2026; PCAC review July 24, 2026 (cerebral ischemia, migraine, trigeminal neuralgia). WADA: S0.
Source: Fnx Performance Peptide Research Database, a synthesis of the scientific and regulatory literature, not medical advice. For medical questions, consult a qualified physician.